Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: A prospective, uncontrolled, pilot study

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 1, 2003, Pages 28-35

  Hanai, Hiroyuki ^c   Watanabe, Fumitoshi ^d   Takeuchi, Ken ^d   Iida, Takayuki ^d   Yamada, Masami ^d   Iwaoka, Yasushi ^d   Saniabadi, Abby ^a   Matsushita, Isao ^d   Sato, Yoshihiko ^d   Tozawa, Kotaro ^d   Arai, Hajime ^d   Furuta, Takahisa ^d   Sugimoto, Ken ^d   Bjarnaso, Ingvar ^b  

^a JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELLULOSE ACETATE; CORTICOSTEROID; CYTOKINE; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GRANULOCYTE; HUMAN; LEUKAPHERESIS; MACROPHAGE; MALE; MONOCYTE; RELAPSE; REMISSION; SURVIVAL TIME; ULCERATIVE COLITIS;

EID: 10744219963     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcgh.2003.50005     Document Type: Article

References (45)

1. Shanahan F. Crohn's disease. Lancet 2002;359:62-69.
2. Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
3. Bjarnason I, Macpherson A, Menzies IS. Intestinal permeability: the basics. In: Sutherland LR, Collins SM, Martin F, McLeod RS, Targan SR, Wallace JL, et al., eds. Inflammatory bowel disease: basic research, clinical implications and trends in therapy. Dordrech, The Netherlands: Kluwer Academic, 1994:53-70.
4. Bjarnason I, Macpherson A, Somasundaram S, Teahon K. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease. Can J Gastroenterol 1993;7:160-169.
5. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-1581.
6. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-26.
7. Nikolaus S, Bauditz J, Gionchetti P. Increased secretion of proinflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998;42:470-476.
8. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-298.
9. Lampinen M, Carlson M, Sangfelt P. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001;46:2004-2009.
10. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-493.
11. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000;6:21-33.
12. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978;74:501-503.
13. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-674.
14. Brannigan AE, O'Connell PR, Hurley H. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-366.
15. Allison MC, Dhillon AP, Lewis WG, Pounder RE, eds. Inflammatory bowel disease. London: Mosby, 1998.
16. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
17. Limburg P, David M, Ahlquist A, Sandborn WJ. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-2837.
18. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand J Gastroenterol 1999;34:50-54.
19. Lee A, Whyte M, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993;54:283-288.
20. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422-4428.
21. Truelove SC, Jewell DP. Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet 1974;1:1067-1070.
22. Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis: a prospective, randomized, double blind clinical trial. Gastroenterology 1983;85:351-357.
23. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013.
24. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative colitis? J Clin Gastroenterol 1995;20:280-284.
25. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-2008.
26. Stack WA, Long RG, Hawkey CJ. Short and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998;12:973-978.
27. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Lawson GM. Cyclosporine enemas for treatment-resistant, mildly to moderately active left-sided ulcerative colitis. Am J Gastroenterol 1993;88:640-645.
28. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanaur S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-185.
29. Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48-63.
30. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ectotherapeutics. Gastroenterology 2001;120:622-635.
31. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998;10:411-413.
32. Ohara M, Saniabadi AR, Hirata I, Kasukawa R. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21:989-994.
33. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 1998;2:134-141.
34. Rembacken BJ, Newbould HE, Richards SJ, Misbah SA, Dixon ME, Chalmers DM, Axon A. Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effect. Ther Apher 1998;2:93-96.
35. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Saniabadi AR. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001;16:1-9.
36. Truelove SC, Witts LJ. Cortisone in the treatment of ulcerative colitis: final report on a therapeutic trial. BMJ 1955;2:1041-1048.
37. Schroeder K, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625-1629.
38. Jewell DP. Ulcerative colitis. In: Feldman M, Scharschmitdt BF, Sleisenger MH, eds. Gastrointestinal and liver disease. 6th ed. Philadelphia: Saunders, 1998:1735-1761.
39. Malech MI, Callin JI. Neutrophils in human disease. N Engl J Med 1987;317:687-694.
40. Weiss GJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-376.
41. Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol Hepatol 1993;5:79-84.
42. Wallach JL, Granger DN. Pathogenesis of NSAID gastropathy: are neutrophils the culprits? Trends Pharmacol Sci 1992;13:129-130.
43. Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease: neuro-immuno-physiology of the gastrointestinal mucosa. Ann N Y Acad Sci 1992;664:103-115.
44. Kashiwagi N, Saniabadi A, Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-1341.
45. D'Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM. Human neutrophil Fc receptor mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 1994;100:173-179.